D020381Chemicals & DrugsD12.644.276.374.465.517D12.776.467.374.465.517D23.529.374.465.51746980.922722Interleukin-17prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonMedicine-RheumatologyMicrobiology31479549Lebwohl MG, Gordon KB, Gallo G, Zhang L, Paul CJournal of the European Academy of Dermatology and Venereology : JEADVIxekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.J Eur Acad Dermatol Venereol2019-11-07T00:00:002019Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.31655974Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin MQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitationIxekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.Qual Life Res2019-10-26T00:00:002019Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.32045273Caldarola G, Pirro F, Di Stefani A, Talamonti M, Galluzzo M, D'Adamio S, Magnano M, Bernardini N, Malagoli P, Bardazzi F, Potenza C, Bianchi L, Peris K, De Simone CExpert opinion on biological therapyClinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opin Biol Ther. 2020 06; 20(6):665-672.Expert Opin Biol Ther2020-02-17T00:00:002020Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.31287604van Vugt LJ, van den Reek JMPA, Meulewaeter E, Hakobjan M, Heddes N, Traks T, Kingo K, Galluzzo M, Talamonti M, Lambert J, Coenen MJH, de Jong EMGJJournal of the European Academy of Dermatology and Venereology : JEADVResponse to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts. J Eur Acad Dermatol Venereol. 2020 Jan; 34(1):112-118.J Eur Acad Dermatol Venereol2019-08-05T00:00:002019Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.34320346Polese B, Thurairajah B, Zhang H, Soo CL, McMahon CA, Fontes G, Hussain SNA, Abadie V, King ILCell reportsProstaglandin E2 amplifies IL-17 production by ?d T cells during barrier inflammation. Cell Rep. 2021 07 27; 36(4):109456.Cell Rep2021-07-27T00:00:002021Prostaglandin E2 amplifies IL-17 production by ?d T cells during barrier inflammation.ShabaanaKhaderShabaana Khader41.7886000000000087.598699999999994229Khader, ShabaanaProfessor5.64610.020594646research area of0.831080.078498998subject area forSurgeryUniversity of ChicagoMarkTalamontiMark Talamonti41.78927490000000-87.601250000000002316Talamonti, MarkClinical ProfessorStevenLevinSteven Levin41.78927490000000-87.601250000000002585Levin, StevenClinical Assistant ProfessorKennethGordonKenneth Gordon41.78927490000000-87.60125000000000340Gordon, KennethMaria-LuisaAlegre2mNlDqYHHMzMknJtY0fp/Cv/+94=Maria-Luisa Alegre41.78927490000000-87.60125000000000481Alegre, Maria-LuisaProfessortrue1true1ProfessorProfessortrue1ProfessorProfessortrue1Clinical Assistant ProfessorClinical Assistant Professortrue1Clinical ProfessorClinical ProfessorOrthopaedic Surg & Rehab Med